BioLineRx (BLRX) Share-based Compensation (IS) (2014 - 2025)
BioLineRx (BLRX) posted Share-based Compensation (IS) of $48000.0 for Q4 2025, down 52.48% on a QoQ basis from $101000.0 in Q3 2025, and up 131.17% year-over-year from $20764.0 in Q4 2024.
BioLineRx (BLRX) has 12 years of Share-based Compensation (IS) data on file, last reported at $48000.0 in Q4 2025.
- In Q4 2025, Share-based Compensation (IS) rose 131.17% year-over-year to $48000.0; the TTM figure through Dec 2025 stood at $396000.0 (down 65.11% YoY), while the FY2025 annual figure was $396000.0, down 65.11% from the prior year.
- Share-based Compensation (IS) slipped to $48000.0 in Q4 2025, from $101000.0 in the prior quarter.
- Across five years, Share-based Compensation (IS) topped out at $1.0 million in Q4 2022 and bottomed at -$154000.0 in Q4 2024.
- A 5-year average of $379600.0 and a median of $376000.0 in 2021 frame the typical range for Share-based Compensation (IS).
- Annual changes were most pronounced in 2022 — Share-based Compensation (IS) soared 167.26% — and 2024, when it slumped 116.58%.
- Year by year, Share-based Compensation (IS) stood at $391000.0 in 2021, then soared by 167.26% to $1.0 million in 2022, then decreased by 11.1% to $929000.0 in 2023, then slumped by 116.58% to -$154000.0 in 2024, then soared by 131.17% to $48000.0 in 2025.
- The last three Share-based Compensation (IS) figures came in at $48000.0 (Q4 2025), $101000.0 (Q3 2025), and $53000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (IS) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.45 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 14.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | 48,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 48,000.00 |
| Dec 31, 2025 | 48,000.00 |
| Sep 30, 2025 | 101,000.00 |
| Sep 30, 2025 | 101,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Mar 31, 2025 | 194,000.00 |
| Mar 31, 2025 | 194,000.00 |
| Dec 31, 2024 | -154,000.00 |
| Dec 31, 2024 | -154,000.00 |
| Sep 30, 2024 | 319,000.00 |
| Sep 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 437,000.00 |
| Jun 30, 2024 | 437,000.00 |
| Mar 31, 2024 | 533,000.00 |
| Mar 31, 2024 | 533,000.00 |
| Dec 31, 2023 | 929,000.00 |
| Dec 31, 2023 | 929,000.00 |
| Sep 30, 2023 | 472,000.00 |
| Sep 30, 2023 | 472,000.00 |
| Jun 30, 2023 | 485,000.00 |
| Jun 30, 2023 | 485,000.00 |
| Mar 31, 2023 | 435,000.00 |
| Mar 31, 2023 | 435,000.00 |
| Dec 31, 2022 | 1.05 Mn |
| Dec 31, 2022 | 1.05 Mn |
| Sep 30, 2022 | 614,000.00 |
| Sep 30, 2022 | 614,000.00 |
| Jun 30, 2022 | 330,000.00 |
| Jun 30, 2022 | 330,000.00 |
| Mar 31, 2022 | 256,000.00 |
| Mar 31, 2022 | 256,000.00 |
| Dec 31, 2021 | 391,000.00 |
| Dec 31, 2021 | 391,000.00 |
| Sep 30, 2021 | 272,000.00 |
| Sep 30, 2021 | 272,000.00 |
| Jun 30, 2021 | 361,000.00 |
| Jun 30, 2021 | 361,000.00 |
| Mar 31, 2021 | 471,000.00 |
| Mar 31, 2021 | 471,000.00 |
| Dec 31, 2020 | 154,000.00 |
| Dec 31, 2020 | 154,000.00 |
| Sep 30, 2020 | 196,000.00 |
| Sep 30, 2020 | 196,000.00 |
| Jun 30, 2020 | 259,000.00 |
| Jun 30, 2020 | 259,000.00 |
| Mar 31, 2020 | 663,000.00 |
| Mar 31, 2020 | 663,000.00 |
| Dec 31, 2019 | 589,000.00 |
| Dec 31, 2019 | 589,000.00 |
| Sep 30, 2019 | 397,000.00 |
| Sep 30, 2019 | 397,000.00 |
| Jun 30, 2019 | 489,000.00 |
| Jun 30, 2019 | 489,000.00 |
| Mar 31, 2019 | 284,000.00 |
| Mar 31, 2019 | 284,000.00 |
| Dec 31, 2018 | 400,000.00 |
| Dec 31, 2018 | 400,000.00 |
| Sep 30, 2018 | 682,000.00 |
| Sep 30, 2018 | 682,000.00 |
| Jun 30, 2018 | 528,000.00 |
| Jun 30, 2018 | 528,000.00 |
| Mar 31, 2018 | 916,000.00 |
| Mar 31, 2018 | 916,000.00 |
| Dec 31, 2017 | 199,000.00 |
| Dec 31, 2017 | 199,000.00 |
| Sep 30, 2017 | 451,000.00 |
| Sep 30, 2017 | 451,000.00 |
| Jun 30, 2017 | 386,000.00 |
| Jun 30, 2017 | 386,000.00 |
| Mar 31, 2017 | 472,000.00 |
| Mar 31, 2017 | 472,000.00 |
| Dec 31, 2016 | 116,000.00 |
| Dec 31, 2016 | 116,000.00 |
| Sep 30, 2016 | 377,000.00 |
| Sep 30, 2016 | 377,000.00 |
| Jun 30, 2016 | 296,000.00 |
| Jun 30, 2016 | 296,000.00 |
| Mar 31, 2016 | 286,000.00 |
| Mar 31, 2016 | 286,000.00 |
| Dec 31, 2015 | 382,000.00 |
| Dec 31, 2015 | 382,000.00 |
| Sep 30, 2015 | 283,000.00 |
| Sep 30, 2015 | 283,000.00 |
| Jun 30, 2015 | 253,000.00 |
| Jun 30, 2015 | 253,000.00 |
| Mar 31, 2015 | 234,000.00 |
| Mar 31, 2015 | 234,000.00 |
| Dec 31, 2014 | 274,000.00 |
| Dec 31, 2014 | 274,000.00 |
| Sep 30, 2014 | 283,000.00 |
| Sep 30, 2014 | 283,000.00 |
| Jun 30, 2014 | 212,000.00 |
| Jun 30, 2014 | 212,000.00 |
| Mar 31, 2014 | 286,000.00 |
| Mar 31, 2014 | 286,000.00 |